- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT03526978
An Immunogenicity and Safety Study of Sabin Inactivated Poliovirus Vaccine (Vero Cell) in 2-month-old Infants
22. januar 2019 opdateret af: Sinovac Biotech Co., Ltd
A Randomized, Double-blind, Controlled Clinical Trial to Evaluate the Immunogenicity and Safety of Sabin Inactivated Poliovirus Vaccine (Vero Cell) in 2-month-old Infants
The purpose of this phase III study is to evaluate the immunogenicity and safety of Sabin Inactivated Poliovirus Vaccine (Vero cell) in 2-month-old infants.
Studieoversigt
Status
Afsluttet
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
The study is a randomized, double-blind, controlled randomized, double-blind, controlled clinical trial clinical trial.
The purpose of this study is to evaluate the immunogenicity and safety of Sabin Inactivated Poliovirus Vaccine (Vero cell) manufactured by Sinovac Vaccine Technology Co., Ltd in 2-month-old infants.
The control vaccine is a commercialized Inactivated Poliovirus Vaccine manufactured by Sanofi Pasteur company.
1200 healthy infants between 60-90 days will be randomly assigned into experimental group or control group in the ratio 1:1.
Undersøgelsestype
Interventionel
Tilmelding (Faktiske)
1200
Fase
- Fase 3
Kontakter og lokationer
Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.
Studiesteder
-
-
Jiangsu
-
Pizhou, Jiangsu, Kina, 221300
- Pizhou county Center for Disease Control and Prevention
-
-
Deltagelseskriterier
Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.
Berettigelseskriterier
Aldre berettiget til at studere
1 måned til 2 måneder (Barn)
Tager imod sunde frivillige
Ja
Køn, der er berettiget til at studere
Alle
Beskrivelse
Inclusion Criteria:
- Healthy volunteer between 60-90 days old;
- Healthy volunteers who fulfill all the required conditions for receiving the investigational vaccine as established by medical history and clinical examination and determined by investigators;
- Proven legal identity;
- Participants or guardians of the participants should be capable of understanding the written consent form, and such form should be signed prior to enrolment;
- Complying with the requirement of the study protocol;
Exclusion Criteria:
- Prior vaccination with Poliovirus Vaccine;
- History of allergy to any vaccine, or any ingredient of the vaccine, or serious adverse reaction(s) to vaccination, such as urticaria, dyspnea, angioneurotic edema, abdominal pain, etc;
- Congenital malformation, developmental disorders, genetic defects, or severe malnutrition;
- Autoimmune disease or immunodeficiency/immunosuppressive;
- Severe nervous system disease (epilepsy, seizures or convulsions) or mental illness;
- Diagnosed coagulation function abnormal (e.g., coagulation factor deficiency, coagulation disorder, or platelet abnormalities) , or obvious bruising or coagulation disorders;
- Any immunosuppressant, cytotoxic medicine, or inhaled corticosteroids (except corticosteroid spray for treatment of allergic rhinitis or corticosteroid treatment on surface for acute non-complicated dermatitis) prior to study entry;
- Blood product prior to study entry;
- Any other investigational medicine(s) within 30 days prior to study entry;
- Any live attenuated vaccine within 14 days prior to study entry;
- Any subunit vaccine or inactivated vaccine within 7 days prior to study entry;
- Acute disease or acute stage of chronic disease within 7 days prior to study entry;
- Axillary temperature > 37.0 °C;
- Any other factor that suggesting the volunteer is unsuitable for this study based on the opinions of investigators;
Studieplan
Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Forebyggelse
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Dobbelt
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: Experimental Group
The investigational vaccine was manufactured by Sinovac Vaccine Technology Co., Ltd. Intervention: investigational sIPV |
Three intramuscular injections of the investigational vaccine (0.5 ml) on Day 0, Day 30 and Day 60 respectively; Single intramuscular injection of the investigational vaccine (0.5 ml) at 18 months; Intervention: investigational sIPV
|
|
Aktiv komparator: Control Group
The control vaccine was manufactured by Sanofi Pasteur Company.
Intervention: control IPV
|
Three intramuscular injections of the control vaccine (0.5 ml) on Day 0, Day 30 and Day 60 respectively; Single intramuscular injection of the control vaccine (0.5 ml) at 18 months; Intervention:control IPV
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
The seroconversion rates (SCRs) of each group after primary immunization.
Tidsramme: 90 days
|
Subjects whose pre-immune antibody level < 1:8 and post-immune antibody level ≥ 1:8, or those whose pre-immune antibody level ≥ 1:8 and the increase of post-immune antibody level ≥ 4 folds are considered seroconverted.
Primary vaccination schedule: 3 doses with one month interval between doses (i.e., month 0, 1, 2).
|
90 days
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
The incidences of solicited adverse events (AEs) of each group.
Tidsramme: 7 days
|
Solicited AEs occurred within 7 days after each injection will be collected.
|
7 days
|
|
The incidences of unsolicited adverse events (AEs) of each group.
Tidsramme: 30 days
|
Unsolicited AEs occurred within 30 days after each injection will be collected.
|
30 days
|
|
The incidence of serious adverse events (SAEs) during the period of safety monitoring of each group.
Tidsramme: 90-420 days.
|
SAEs during the period of safety monitoring will be collected.
|
90-420 days.
|
|
The post-immune antibody positive rate of each group after primary immunization.
Tidsramme: 90 days
|
Subjects whose post-immune antibody level ≥ 1:8 are considered antibody positive.
Primary vaccination schedule: 3 doses with one month interval between doses (i.e., month 0, 1, 2).
|
90 days
|
|
The post-immune geometric mean titer (GMT) of each group after primary immunization.
Tidsramme: 90 days.
|
GMT of each group after primary immunization which lasts 60 days.
|
90 days.
|
|
The geometric mean fold increase (GMI) of each group after primary immunization.
Tidsramme: 90 days
|
The GMI is the increase of post-immune GMT from pre-immune GMT.
|
90 days
|
|
The percentage of subjects with antibody ≥ 1:64 of each group after primary immunization.
Tidsramme: 90 days
|
Percentage of subjects with antibody ≥ 1:64 of each group after three-dose
|
90 days
|
|
The antibody positive rate of each group before booster dose.
Tidsramme: 420 days
|
Subjects whose post-immune antibody level ≥ 1:8 are considered antibody positive.
A booster dose at the age of 18months.
|
420 days
|
|
The geometric mean titer (GMT) of each group before booster dose.
Tidsramme: 420 days.
|
GMT of each group before booster dose which occurred at the age of 18months.
|
420 days.
|
|
The geometric mean fold increase (GMI) of each group before booster dose.
Tidsramme: 420 days
|
The GMI is the increase of post-immune GMT from pre-i mmune GMT.
|
420 days
|
|
The percentage of subjects with antibody ≥ 1:64 of each group before booster dose.
Tidsramme: 420 days
|
Percentage of subjects with antibody ≥ 1:64 of each group before booster dose which occurred at the age of 18months.
|
420 days
|
|
The post-immune antibody positive rate of each group after booster dose.
Tidsramme: 570 days
|
Subjects whose post-immune antibody level ≥ 1:8 are co nsidered antibody positive |
570 days
|
|
The post-immune geometric mean titer (GMT) of each group after booster dose.
Tidsramme: 570 days
|
GMT of each group after booster dose.
The booster dose at the age of 18months
|
570 days
|
|
The geometric mean fold increase (GMI) of each group after booster dose.
Tidsramme: 570 days
|
The GMI is the increase of post-immune GMT from pre-immune GMT.
|
570 days
|
|
The percentage of subjecs with antibody ≥ 1:64 of each group after booster dose.
Tidsramme: 570 days
|
Percentage of subjecs with antibody ≥ 1:64 of each group after booster dose which occurred at the age of 18months.
|
570 days
|
Samarbejdspartnere og efterforskere
Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.
Sponsor
Publikationer og nyttige links
Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.
Datoer for undersøgelser
Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.
Studer store datoer
Studiestart (Faktiske)
8. august 2017
Primær færdiggørelse (Faktiske)
18. oktober 2017
Studieafslutning (Faktiske)
18. april 2018
Datoer for studieregistrering
Først indsendt
4. maj 2018
Først indsendt, der opfyldte QC-kriterier
4. maj 2018
Først opslået (Faktiske)
16. maj 2018
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
25. januar 2019
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
22. januar 2019
Sidst verificeret
1. januar 2019
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- PRO-sIPV-3001
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Ingen
Studerer et amerikansk FDA-reguleret enhedsprodukt
Ingen
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .